Welcome to our dedicated page for Agenus news (Ticker: AGEN), a resource for investors and traders seeking the latest updates and insights on Agenus stock.
Agenus Inc. (NASDAQ: AGEN) is a pioneering clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. Agenus is steadfast in its mission to develop innovative immunological therapies aimed at leveraging the body's immune system to combat cancer and other diseases. The company’s diverse product pipeline includes immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc., and vaccine adjuvants through its subsidiary SaponiQx Inc. These products are bolstered by in-house capabilities such as current good manufacturing practice (cGMP) manufacturing and a clinical operations platform.
Agenus has developed several key product candidates, including botensilimab (AGEN1811), a next-generation Fc-engineered CTLA-4 antibody, and balstilimab, a PD-1 antibody. They are currently under investigation for their potential to treat various cancers, particularly difficult-to-treat solid tumors.
The company has achieved significant milestones, including the initiation of various clinical trials for botensilimab and balstilimab. Notably, in April 2024, Agenus announced a one-for-twenty reverse stock split of its issued and outstanding common stock to increase its stock price and meet Nasdaq Capital Market listing requirements. This move is part of a strategic plan to enhance future financing and qualify for inclusion in the Russell Indices.
In its ongoing pursuit of innovative cancer treatments, Agenus recently announced Phase 1 trial results demonstrating encouraging survival rates in patients with metastatic colorectal cancer. The Phase 2 data is expected to be submitted to a major medical conference in the latter half of 2024.
Agenus also engages in strategic partnerships to accelerate its development programs. For instance, a recent agreement with Ligand Pharmaceuticals secures a $100 million capital infusion, specifically aimed at supporting the clinical development and launch readiness of the BOT/BAL combination therapy.
The team at Agenus comprises scientists, researchers, biotechnologists, physicians, and business professionals united by the shared goal of achieving breakthroughs in cancer treatment. This collaborative spirit ensures that Agenus remains at the forefront of transformative cancer therapies, aiming to enhance patient outcomes and extend lives.
For more information, visit www.agenusbio.com or follow @agenus_bio on social media.
Agenus Inc. (NASDAQ: AGEN) has announced a clinical collaboration with Nelum Corp. to evaluate the combination of zalifrelimab, its anti-CTLA-4 antibody, and Nelum's NLM-001 with chemotherapy for first-line advanced pancreatic cancer. The trial aims to assess the safety and efficacy of this combination. Under the agreement, Agenus will supply zalifrelimab, while Nelum will sponsor and conduct the trial, expected to begin enrolling in the first half of 2021. This collaboration is seen as a strategic move to enhance the therapeutic potential of Agenus' pipeline.
Agenus Inc. (NASDAQ: AGEN) announced that Dr. Jennifer Buell, President and COO, and Dr. Steven O’Day, CMO, will participate in the B. Riley Securities’ Oncology Investor Conference on January 20-21, 2021. The conference will feature a fireside chat with Dr. Buell on January 21 from 10:30 am to 11:00 am, accessible via a live webcast. Additionally, both doctors will engage in a panel discussion on novel immunotherapies. Recorded replays will be available on Agenus' Events & Presentations page post-conference.
Agenus Inc. (NASDAQ: AGEN) announced an updated timeline for the Biologics License Application (BLA) filing of balstilimab, necessitated by FDA feedback for a 12-month follow-up on all trial patients and a 6-month follow-up on responders. Two late responses in the clinical trial prompted this strategy adjustment, with the BLA filing now expected in the first half of 2021. The company is also clarifying PD-L1 diagnostic requirements with the FDA. This follow-up will provide data on patients achieving durable disease stabilization through long-term therapy.
Agenus Inc. (NASDAQ: AGEN) has expanded its Phase 2 trial for AGEN1181 in colorectal cancer following a promising clinical response. A significant tumor reduction of 27% was observed in a patient, alongside disease stabilization in 19 out of 41 treated patients. The trial also reported four clinical responses and the potential to treat tumors traditionally unresponsive to immune therapies. The company aims to broaden the patient population benefiting from cancer immunotherapies through innovative combination approaches.
Agenus Inc. (NASDAQ: AGEN) announced Dr. Jennifer Buell, President and COO, will participate in a fireside chat at the Evercore ISI 3rd Annual HealthCONx Conference on December 3, 2020, from 10:55 AM to 11:15 AM EST. Dr. Buell is set to provide updates on clinical programs, specifically AGEN1181, and the company's overall progress. Interested individuals can register for the webinar in advance. A replay will be available post-event on the Agenus website's Events & Presentations page.
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology firm, announced Dr. Jennifer Buell's participation in a fireside chat at the Jefferies 2020 Virtual London Healthcare Conference on November 17, 2020, from 4:25 PM - 4:55 PM GMT. This event will highlight the company’s innovative pipeline of immune therapies, including checkpoint antibodies and vaccines aimed at enhancing immune responses against cancer. Interested parties can register for the webinar and access a replay on the Agenus website.
Agenus Inc. (NASDAQ: AGEN) announced a webcast on November 16, 2020, featuring Dr. Steven O’Day and other key figures discussing AGEN1181 and its Ph1 trial results. Dr. O’Day will review initial responses in patients with microsatellite stable disease and implications of Treg depletion. Dr. Jennifer Buell and Dr. Dhan Chand will outline next steps for AGEN1181 and share insights on its other drug programs, including AGEN2373 and AgenT-797. Registration is available online, and a replay will be accessible on the Agenus website post-event.
Agenus Inc. (NASDAQ: AGEN) announced participation in the Virtual SITC 2020 Immuno-Oncology Event hosted by B. Riley on November 12, 2020. Key executives, including Dr. Steven O'Day and Dr. Jennifer Buell, will lead discussions on Next-Gen Checkpoint Inhibitors and Cell Therapy 2.0. The event includes two panels: The first from 1:00 PM to 2:00 PM ET, and the second from 2:00 PM to 3:00 PM ET. Interested parties can access replays via provided conference IDs.
Agenus focuses on immuno-oncology therapies designed to activate immune responses against cancer.
Agenus Inc. announced a triggered $10M milestone payment from Merck, following the advancement of the ILT4 antibody, MK-4830, into a Phase 2 clinical trial. This novel checkpoint antibody aims to target immune-suppressive cells in tumors. The company is eligible for an additional $85 million in milestones and royalties from sales. Merck is currently evaluating MK-4830 in combination with KEYTRUDA® for treating advanced non-small cell lung cancer. Agenus retains a significant portion of milestones and royalties due to its agreements.
Agenus Inc. (NASDAQ: AGEN) presented seven novel clinical programs at the SITC 2020 Annual Meeting. Key highlights include AGEN1181, showing clinical responses in hard-to-treat tumors and the first report of intratumoral Treg depletion. AGEN1777 offers improved immune performance as an Fc-enhanced TIGIT antibody. AGEN2373 demonstrates clinical benefit without liver toxicity. The proprietary VISION platform predicts treatment responses with high accuracy. Overall, these findings support Agenus's commitment to advancing immuno-oncology therapies.
FAQ
What is the current stock price of Agenus (AGEN)?
What is the market cap of Agenus (AGEN)?
What does Agenus Inc. specialize in?
Where is Agenus Inc. headquartered?
What are the key products of Agenus Inc.?
What recent strategic financial move did Agenus make?
What significant agreement did Agenus secure recently?
What are some recent clinical trial achievements of Agenus?
What is the focus of Agenus' product candidates?
Who are part of the Agenus team?
How does Agenus support its product development?
Where can investors find more information about Agenus?
